Interferon lambda-2, IFN-lambda-2, Interleukin-28A, IL-28A, Ifnl2, Il28a, EG330496.
> 95% by SDS-PAGE & HPLC analyses
The ED50 as determined by an anti-viral assay using human HepG2 cells infected with encephalomyocarditis(EMC) virus is less than 3 ng/ml, corresponding to a specific activity of > 3.3 × 105 IU/mg.
Lyophilized mouse IL-28A although stable at room temperature for 3 weeks, should be stored desiccated below -18°C.
It is recommended to reconstitute the lyophilized IL-28A in sterile water not less than 100µg/ml, which can then be further diluted to other aqueous solutions.
DPVPRATRLP VEAKDCHIAQ FKSLSPKELQ AFKKAKDAIE KRLLEK
DMRC SSHLISRAWD LKQLQVQERP KALQAEVALT LKVWENMTDS A
LATILGQPL HTLSHIHSQL QTCTQLQATA EPKPPSRRLS RWLHRLQ
EAQ SKETPGCLED SVTSNLFRLL TRDLKCVASG DQCV
IL-28A is distantly related to type I interferons and the IL-10 family. Expression of IL-28A is induced by viral infection which interacts with a heterodimeric class II cytokine receptor that consists of interleukin 10 receptor, beta (IL10RB) and interleukin 28 receptor, alpha. IL-28A exhibits common features with type I IFNs such as antiviral activity, antiproliferative activity and in vivo antitumour activity. IL-28A acts similarly to IFNs, but is less effective generally and has activity in a more limited range of cell lines. IFN-ambda 1, IFN-lambda 2 and IFN-lambda 3 are closely positioned genes on human chromosome 19. IL-28A induces ELR(-) CXC chemokine mRNA in human peripheral blood mononuclear cells, in an IFN-gamma-independent manner. IL-28A is able to generate tolerogenic DCs, an activity that could thwart IFN-beta functions. IL-28A produced in response to viral infection, activates both monocytes and macrophages producing a restricted panel of cytokines and therefore is an important factor in activating innate immune responses at the site of viral infection.
NCBI Gene ID: